During the corresponding time, 180 Life Sciences Corp sequentially revenue fell by -52.26 %. While revenue at the 180 Life Sciences Corp's corporate clients
180 Life Sciences's Comment on Sales, Marketing and Customers
The Company operates in the emerging market for tokenized real-world assets (RWAs), competing with digital asset infrastructure providers and financial technology firms that develop tokenization platforms and digital securities infrastructure. Its customers include regulated digital asset platforms, blockchain infrastructure providers, financial institutions exploring tokenized financial products, and large financial institutions and asset managers such as BlackRock, KKR, Apollo, and Hamilton Lane, which have participated in initiatives involving tokenized funds or private market assets. The Company serves institutional and digital capital markets through asset distribution and capital markets activities. It focuses on asset origination, financing, and tokenization infrastructure integration. Its revenue sources include asset yield and financing income from consumer loan portfolios or heavy equipment assets, tokenization and structuring fees, and asset distribution and capital markets activities.
180 Life Sciences Corp. Announces Positive Topline Results from Clinical Pharmacology Study on Novel Solid Cannabidiol Formulation PALO ALTO, Calif., July 30, 2024 180 Life Sciences Corp. (NASDAQ: ATNF) has recently disclosed topline results from a clinical pharmacology study evaluating a new solid formulation of cannabidiol (CBD) designed for enhanced oral bioavailability. Conducted in collaboration with Professor Avi Domb of the Hebrew University, School of Pharmacy, and Professor Elyad Davidson from Hadassah Hospital, the study aimed to elucidate the pharmacokinetic (PK) profiles of the experimental formulations in comparison to Epidiolex, an FDA-approved CBD product used to treat epilepsy.The study eng...
180 Life Sciences’s Comment on Sales, Marketing and Customers
The Company operates in the emerging market for tokenized real-world assets (RWAs), competing with digital asset infrastructure providers and financial technology firms that develop tokenization platforms and digital securities infrastructure. Its customers include regulated digital asset platforms, blockchain infrastructure providers, financial institutions exploring tokenized financial products, and large financial institutions and asset managers such as BlackRock, KKR, Apollo, and Hamilton Lane, which have participated in initiatives involving tokenized funds or private market assets. The Company serves institutional and digital capital markets through asset distribution and capital markets activities. It focuses on asset origination, financing, and tokenization infrastructure integration. Its revenue sources include asset yield and financing income from consumer loan portfolios or heavy equipment assets, tokenization and structuring fees, and asset distribution and capital markets activities.
Sources:
180 Life Sciences Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 180 Life Sciences Corp’s corporate clients.
For your research, we’ve provided 9 tables on 180 Life Sciences Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
179.71 %